← Leaderboards
Wing C. Chan
University Of Nebraska Medical Center
$16,090,658
Attributed
$18,855,209
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$18,855,209 · 9
By mechanism
U01$14,219,534 · 3
R01$1,922,023 · 1
P50$1,153,023 · 2
UH3$864,147 · 1
UH2$397,085 · 1
R41$299,397 · 1
Top collaborators
- Javeed Iqbal14 shared
- Muhammed Murtaza4 shared
- Stephan Wade Morris1 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Javeed Iqbal$5,566,166
- R Lee Mosley$4,668,927
- David Morris Colcher$6,573,695
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularDiagnosisSpecimenSamplingClassificationGene ExpressionLymphomaS LymphomaPeripheralGene Expression ProfilingValidationTissuesT-Cell LymphomaSubgroupImmunoblastic LymphadenopathyTumorPathologicImmunophenotypingParaffin EmbeddingDiagnosticGene Expression ProfileTissue EmbeddingPrognosticFormalin
Grant awards (34)
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis$463,981
R01 · FY2024 · CA
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$348,939
U01 · FY2024 · CA
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis$478,632
R01 · FY2023 · CA
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$359,942
U01 · FY2023 · CA
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis$478,632
R01 · FY2022 · CA
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$359,962
U01 · FY2022 · CA
Biospecimen Bank$176,485
P50 · FY2022 · CA · contact PI
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis$500,778
R01 · FY2021 · CA
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$391,146
U01 · FY2021 · CA
Molecular diagnostic and prognostic signatures for PTCL$246,546
UH3 · FY2021 · CA
Biospecimen Bank$166,311
P50 · FY2021 · CA · contact PI
Molecular diagnostic and prognostic signatures for PTCL$301,020
UH3 · FY2020 · CA
Biospecimen Bank$170,878
P50 · FY2020 · CA · contact PI
Molecular diagnostic and prognostic signatures for PTCL$316,581
UH3 · FY2019 · CA
Biospecimen Bank$160,609
P50 · FY2019 · CA · contact PI
Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)$299,397
R41 · FY2018 · CA
Molecular diagnostic and prognostic signatures for PTCL$191,615
UH2 · FY2018 · CA
Biospecimen Bank$174,611
P50 · FY2018 · CA · contact PI
Molecular diagnostic and prognostic signatures for PTCL$205,470
UH2 · FY2017 · CA
Gene expression profiling and pathway targeted therapy in peripheral T-cell$98,078
P50 · FY2011 · CA · contact PI
Gene expression profiling and pathway targeted therapy in peripheral T-cell$103,081
P50 · FY2010 · CA · contact PI
Molecular Signatures to Improve Diagnosis and Outcome Pr$1,720,841
U01 · FY2009 · CA · contact PI
Molecular Signatures to Improve Diagnosis and Outcome Pr$369,275
U01 · FY2009 · CA · contact PI
Gene expression profiling and pathway targeted therapy in peripheral T-cell$102,970
P50 · FY2009 · CA · contact PI
Molecular Signatures to Improve Diagnosis and Outcome Pr$1,674,031
U01 · FY2008 · CA · contact PI
Molecular Signatures to Improve Diagnosis and Outcome Pr$1,424,442
U01 · FY2007 · CA · contact PI
Molecular Signatures to Improve Diagnosis and Outcome Pr$1,664,061
U01 · FY2006 · CA · contact PI
Molecular Signatures to Improve Diagnosis and Outcome Pr$100,000
U01 · FY2006 · CA · contact PI
Molecular Signatures to Improve Diagnosis and Outcome Pr$1,714,884
U01 · FY2005 · CA
MOLECULAR CLASSIFICATION OF B-CELL LYMPHOMA$54,140
U01 · FY2004 · CA
MOLECULAR CLASSIFICATION OF B-CELL LYMPHOMA$1,112,349
U01 · FY2003 · CA
MOLECULAR CLASSIFICATION OF B-CELL LYMPHOMA$761,489
U01 · FY2002 · CA
MOLECULAR CLASSIFICATION OF B-CELL LYMPHOMA$1,116,146
U01 · FY2001 · CA
MOLECULAR CLASSIFICATION OF B-CELL LYMPHOMA$1,047,887
U01 · FY2000 · CA